Estrogen production and metabolism play critical roles in the development and pathogenesis of endometrial carcinoma. Cytochrome P450 1B1 (CYP1B1) and catechol-Omethyltransferase (COMT) are two key enzymes in the estrogen metabolism pathway that result in the hydroxylation and conjugation of estradiol, respectively. We evaluated the association between the CYP1B1 Leu432Val and CYP1B1 Asn453Ser polymorphisms and the COMT Val158Met polymorphism and invasive endometrial cancer risk in a case-control study nested within the Nurses' Health Study (n 222 cases, 666 controls). We also evaluated whether body mass index (BMI), postmenopausal hormone (PMH) use and cigarette smoking modified the associations of the CYP1B1 and COMT genotypes and endometrial cancer risk. Conditional logistic regression was used to calculate the adjusted odds ratios (OR) and 95% confidence intervals (CI) to quantify the risk of endometrial cancer among subjects who had at least one variant allele compared with subjects who were homozygous for the wild-type allele. Carriers of the CYP1B1 Ser allele had a statistically significant decreased risk of endometrial cancer (OR 0.62; 95% CI, 0.42EE0.91); there was no significant association between the CYP1B1 Val allele and endometrial cancer risk (OR 1.10; 95% CI, 0.75EE1.59). Compared with the COMT Val/Val wildtype genotype, the adjusted OR of endometrial cancer for women with the COMT Val/Met or COMT Met/Met genotype was 0.96 (95% CI, 0.65EE1.43). We did not observe any effect modification by BMI, PMH use and cigarette smoking for the CYP1B1 and COMT genotypes. Our data suggest, that the CYP1B1 Ser allele may decrease endometrial cancer risk by altering the production of catechol estrogens. However, further studies are warranted to elucidate the role of CYP1B1 in endometrial cancer.
Introduction
The production and metabolism of estrogen play critical roles in the pathogenesis and development of hormone-related cancers, including endometrial carcinoma. Inherited variability in the synthesis and metabolism of steroid hormones may affect cancer risk by contributing to individual differences in serum and cellular levels of steroidal parent hormones and hormone metabolites (1, 2) . Polymorphisms in estrogen-metabolizing genes may cause alterations in their biological function and thus potentially contribute to individual disease susceptibilities. We hypothesized that functionally relevant polymorphisms in COMT and CYP1B1 may display individual, as well as additive, effects on endometrial cancer susceptibility.
Cytochrome P450 1B1 (CYP1B1) is a phase I enzyme that catalyzes the conversion of 17b-estradiol (E2) to the catechol estrogens, 4-hydroxyestradiol (4-OH-E2) and 2-hydroxyestradiol (2-OH-E2) and is involved in the activation of polycyclic aromatic hydrocarbons (3) . Several single nucleotide polymorphisms have been identified in CYP1B1. The CYP1B1 Leu432Val and Asn453Ser polymorphisms located in exon 3, which encodes the catalytically important heme-binding domain of the enzyme, were selected as candidate susceptibility alleles (4, 5) . These polymorphisms are biologically relevant and functional (6EE9), and have been studied in relation to other hormonally relevant cancers, such as breast cancer (5, 10EE12) . Two additional polymorphisms, Arg48Gly and Ala119Ser, also result in amino acid substitutions and are tightly linked (4) . However, McLellan et al. (13) observed no kinetic differences in E2 hydroxylation activities, and concluded that these amino acid substitutions led to similar catalytic properties to those of the wildtype genotype. All CYP1B1 variants form 4-OH-E2 as their main product (6, 8) . Hanna et al. (8) determined that inherited CYP1B1 variants displayed higher estradiol 2-and 4-hydroxylation activities compared with their wildtype enzyme. Furthermore, the ratio of product formation of 4-OH-E2 to 2-OH-E2 was higher for CYP1B1 variants compared with their wildtype counterpart (6, 8) , potentially contributing to higher tissue levels of 4-OH-E2 (8) .
Catechol-O-methyltransferase (COMT) is a phase II enzyme that is involved in the conjugation and inactivation of catechol estrogens (14) . COMT catalyzes the methylation of catechol estrogens to less polar monomethyl ethers. O-Methylation increases the concentrations of 4-methoxyestradiol (4-MeO-E2) and 2-methoxyestradiol (2-MeO-E2): 2-MeO-E2 possesses anti-proliferative, cytotoxic and apoptotic activity therefore decreasing the potential for DNA damage (15EE19). Lachman et al. (20) identified a functional polymorphism in the COMT gene, a G 3 A transition at codon 158 in exon 4, leading to a substitution of methionine for valine that results in a thermolabile enzyme with reduced activity. Individuals who are homozygous for this low activity Met allele have a 3EE4-fold decrease in activity, resulting in possible increased levels of circulating catechol estrogens and the decreased formation of the antitumorigenic 2-methoxyestradiol (20EE24). Therefore, the COMT Met allele may increase the risk of endometrial cancer because of the decreased ability to methylate and detoxify catechol estrogens or because of the decreased production of the intermediate products of catechol estrogen metabolism.
The CYP1B1 polymorphisms involved in estradiol hydroxylation and catechol estrogen formation and the COMT polymorphisms involved in catechol estrogen degradation have not been well studied in relation to endometrial cancer. The expression of COMT and CYP1B1 in the uterus and the tissuespecific hydroxylation of E2 to reactive catechol estrogens underscore the genes' potential importance in endometrial carcinogenesis (9, 15, 25EE27) . In the present study, we assessed the relationship between the CYP1B1 Leu432Val, Asn453Ser polymorphisms, and the COMT Val158Met polymorphism and invasive endometrial cancer risk in a case-control study nested within the Nurses' Health Study (NHS) cohort.
Materials and methods

Study population
The NHS began in 1976 when 121 700 US registered nurses between the ages of 30EE55 years completed a self-administered questionnaire on their medical histories and baseline health-related exposures. Information regarding endometrial cancer risk factors was obtained from biennial questionnaires and a questionnaire completed at the time of blood collection. These questionnaires include data on reproductive variables, oral contraceptive (OC) and postmenopausal hormone (PMH) use, body mass index (BMI), cigarette smoking and (since 1980) dietary intake. Women were defined as postmenopausal at the time of blood collection if they reported having a bilateral oophorectomy or no menstrual cycle within the last 12 months before blood draw. Menopausal status and PMH use were updated until the date of diagnosis for cases and matched controls. Between 1989 and 1990, blood samples were collected from 32 826 women. Approximately 97% of the samples were returned within 26 h of blood draw. Upon receipt, these samples were immediately centrifuged, aliquoted into plasma, RBCs and buffy coat fractions, and stored in liquid nitrogen freezers. Subsequent follow-up has been 498% for this subcohort of NHS participants who have given blood.
In our study, we included both incident and prevalent endometrial cancer cases from this NHS blood cohort. Eligible incident cases consisted of women with pathologically confirmed invasive endometrial cancer that had been diagnosed anytime after blood collection and up to June 1, 1998, with no previously diagnosed cancer except for non-melanoma skin cancer. Prevalent cases were defined as having pathologically confirmed invasive endometrial cancer diagnosed between 1976 and the date of blood collection, with no previously diagnosed cancer except for non-melanoma skin cancer. Controls for both incident and prevalent cases were randomly selected participants who had given a blood sample, had not had a hysterectomy and were free of diagnosed cancer (except non-melanoma skin cancer) up to and including the interval in which the case was diagnosed. Controls were matched to cases 3:1 according to year of birth, menopausal status at blood draw and at the cycle prior to diagnosis, and PMH use at time of blood draw (current versus not current users). Controls were also matched to cases by time of day of blood collection, month of blood return and fasting status at blood draw for possible plasma hormone analyses. This case-control study consists of 104 incident endometrial cancer cases, 118 prevalent endometrial cancer cases and 666 matched controls. In addition, 234 women who were controls in a nested casecontrol study of breast cancer, and who had not had a hysterectomy and were free of cancer other than non-melanoma skin cancer were also genotyped for the three polymorphisms. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women's Hospital, Boston, Massachusetts.
CYP1B1 genotyping assay
Genotyping assays were performed by pyrosequencing (Pyrosequencing, Uppsala, Sweden) and by automated DNA sequencing on the ABI 377X using BigDye-terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, Foster City, CA). The primers, probes and conditions for pyrosequencing and sequencing are available upon request.
COMT genotyping assay COMT genotypes were identified by PCREERFLP methods described previously (28) . All of the genotyping was performed by laboratory personnel blinded to case-control status, and blinded quality control samples were inserted to validate genotyping identification procedures; concordance for blinded samples was 100%.
Statistical analysis
We used a x 2 test to assess whether the CYP1B1 and COMT genotypes were in HardyEEWeinberg equilibrium and to determine P values for differences in genotype frequencies between cases and controls. The associations between CYP1B1 and COMT genotypes and endometrial cancer risk were examined by using conditional and unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). In addition to the matching factors, analyses were also adjusted for endometrial risk factors: BMI at age 18 (kg/m 2 ) (continuous); weight gain since age 18 (55, 5EE19.9 and !20 kg); age at menarche (512, 12, 13 and 413 years); parity/age at first birth (nulliparous, !1 child/age at first birth 24 years, !1 child/age at first birth 424 years); pack-years of smoking (never smoker, 530, and !30 pack-years); menopausal status at diagnosis (premenopausal, postmenopausal, dubious and/or missing menopausal status); PMH use at diagnosis (current/not current) age at menopause (548 years, 48 age 550, 50 age 553, !53 years); first degree family history of endometrial cancer (yes/no), first degree family history of colorectal cancer (yes/no). Indicator variables for the different genotypes were created by using individuals homozygous for the wild-type allele, the Leu/Leu, the Asn/Asn and the Val/Val, as the reference category for CYP1B1 Leu432Val, CYP1B1 Asn453Ser and COMT Val158Met, respectively. Gene dosage effects were modeled by assigning the values of 0, 1 and 2 to a genotype trend variable according to the subject's number of variant alleles (zero, one and two variant alleles, respectively). If no gene dosage effect was observed, the genotypes were also evaluated by using the dichotomous variable carrier versus non-carrier. Unconditional logistic regression models were used for all stratified analyses. Unconditional logistic regression models assessing the main effect of the genotype on endometrial cancer risk also included a second control group from the nested breast cancer case-control study (10) . Because of sample size considerations, we combined heterozygotes and homozygote variants in the interaction analyses. To test statistical interactions between COMT and CYP1B1 genotypes and environmental exposures in unconditional logistic regression models, we first used a likelihood ratio test (LRT) to compare nested models that included terms for all combinations of the genotypes and levels of environmental exposures to the models with indicator variables for the main effects only (nominal LRT). We also modeled COMT and CYP1B1 genotypes as ordinal variables and environmental exposures as continuous variables to assess the statistical significance of interactions by LRT test of a single interaction term (ordinal LRT). To test the statistical interaction between the COMT genotype and the CYP1B1 genotypes, a similar approach was employed. Case-only analysis was conducted to investigate the association between the CYP1B1 and COMT genotypes and the degree of differentiation of endometrial cancer utilizing the x 2 test. All P-values are two-sided. We used the SAS (SAS Institute, Cary, NC) statistical package for all analysis (SAS, Version 8.2 for Unix).
Results
The distributions of the CYP1B1 Leu432Val, CYP1B1 Asn453Ser and COMT Val158Met genotypes were compared between incident and prevalent endometrial cancer cases to determine whether the variant alleles were associated with survival. The COMT Val158Met and CYP1B1 Leu432Val genotype frequencies were similar among incident cases and prevalent cases. In caseEEcase analysis for CYP1B1 Asn453Ser, the genotype frequencies for incident cases [Asn/Asn, n 80 (78%), Asn/Ser, n 18 (18%), Ser/Ser, n 4 (4%)] were marginally significantly different from prevalent cases [Asn/ Asn, n 78 (67%), Asn/Ser, n 36 (31%), Ser/Ser, n 2 (2%); x 2 5.82, df 2, P 0.05]. This finding is most probably attributable to small sample size and chance; therefore, all incident and prevalent cases were combined for all statistical analysis. In addition, the number of deaths from endometrial cancer among the prevalent cases [n 2 (25% of all deaths among prevalent cases)] was not different from the number of deaths observed among the incident cases [n 6 (50% of all deaths among incident cases)] from endometrial cancer (P 0.10).
Our study population included 222 endometrial cancer cases and 666 matched controls. However, for the CYP1B1 Leu432Val polymorphism, our analyses included 219 matched case-control sets and for the CYP1B1 Asn453Ser polymorphism, analyses included 218 matched case-control sets. For the COMT Val158Met polymorphism, analyses included 215 matched case-control sets; numbers vary for the different analyses because of missing genotype information. All analyses were also run excluding African-Americans and Asians (n 4); results did not appreciably change (data not shown). The mean age of the women at diagnosis was 59.0 years [standard deviation (SD), 7.8]. Cases and controls had similar ethnicity, use of oral contraceptives (38.3% versus 39.9%) and alcohol use prior to diagnosis (4.8 versus 5.8 g) (Table I) . Compared with controls, cases had an earlier age of menarche (12.4 versus 12.6 years), later age of menopause (50.0 versus 49.3 years) and among parous women, an earlier age at first birth (21.5 versus 22.9 years). Cases also had a greater BMI prior to diagnosis (27.8 versus 25.5 kg/m 2 ) and gained more weight between age 18 and diagnosis (16.3 versus 11.0 kg). Cases were more likely to have a first-degree family history of uterine cancer (8.6% versus 4.1%); a first-degree family history of colorectal cancer (23.0% versus 17.1%); to have never smoked (49% versus 41%); to be current users of PMH use at diagnosis (48.5% versus 32.7%); and among current PMH users, cases were more likely to use estrogen alone (52.3% versus 29.9%) compared with the use of estrogen and progestin.
The prevalence of the CYP1B1 Val allele, the CYP1B1 Ser allele and COMT Met allele among the controls was 0.46, 0.20 and 0.51, respectively, similar to previously published reports in Caucasian women (5,10,28EE30). The genotype distributions of the three polymorphisms among the cases and controls were in HardyEEWeinberg equilibrium.
The CYP1B1 Ser allele was underrepresented among women with endometrial cancer [28% of the cases, and 36% of the controls (x 2 4.75, df 1, P 0.03)]. This is not due to à survivor' effect among the prevalent cases; the prevalence of the Ser allele is lower in the incident case series compared with the prevalent case series. Compared with the Asn/Asn genotype, the adjusted ORs for the Asn/Ser and Ser/Ser genotypes were 0.61 (95% CI, 0.41EE0.91) and 0.67 (95% CI, 0.26EE1.74), respectively (Table II) . A significant gene dosage effect was observed (P 0.02); however, because there were too few homozygote variants, heterozygotes and homozygote variants were combined for all subsequent analyses. Compared with the homozygote wild-type genotype, the adjusted OR for a woman carrying the CYP1B1 Ser allele was 0.62 (95% CI, 0.42EE0.91). Associations were similar after stratification by menopausal status at diagnosis.
There were no significant differences in genotype frequencies for COMT Val158Met and CYP1B1 Leu432Val among (Table IV) . Associations for the COMT genotype and endometrial cancer risk were similar after stratification by menopausal status at diagnosis. Considering our finding with the CYP1B1 Asn453Ser polymorphism, we sought to further define this relationship by including a second population of control women (n 234) from the NHS. A comparison of the population characteristics of the second control group with the first control group revealed no material differences in ethnicity, mean BMI, weight gain since age 18, first-degree family history of endometrial or colorectal cancer, age at first birth, age at menarche and PMH use (data not shown). The association of CYP1B1 Asn453Ser polymorphism with endometrial cancer was fundamentally the same with an adjusted OR of 0.70 (95% CI, 0.49, 0.98). The associations of CYP1B1 Leu432Val and COMT Val158Met and endometrial cancer risk were also similar after inclusion of the second control group (data not shown).
Since CYP1B1 and COMT are involved in estrogen metabolism, we chose BMI and PMH use as potential effect modifiers based on biological plausibility and their potential influence on estrogen levels. We did not observe any statistically significant effect modification by BMI and PMH use for any of the genotypes and endometrial cancer risk (all P for interactions 40.10). CYP1B1 is also involved in the activation of tobacco smoke carcinogens; however, we did not observe effect modification by cigarette smoking for the CYP1BI genotypes and endometrial cancer risk (P for interaction 40.4). Based on a priori hypotheses, we also evaluated geneEEgene interactions between CYP1B1 and COMT, and detected no significant interactions between the different polymorphisms; however, there was only limited power to detect such an association.
Discussion
To our knowledge, this is the first nested case-control study to investigate the association between COMT and CYP1B1 and endometrial cancer in Caucasian women. COMT and CYP1B1 are candidate susceptibility genes involved in the hydroxylation and conjugation of estradiol, respectively, and a woman's ability to inactivate estrogen and its metabolites may serve as an important determinant of risk. Our results suggest that the CYP1B1 Ser allele may decrease a woman's risk of endometrial cancer.
We found no significant association between the CYP1B1 Leu432Val polymorphism and endometrial cancer risk although a recent case-control study of 113 Japanese endometrial cancer patients and 202 healthy controls observed a significant increased risk of endometrial cancer associated with Unconditional logistic regression adjusted for same variables as in e plus PMH use at diagnosis and age at menopause. g P-value for the nominal LRT comparing the nested model that included terms for all combinations of the dichotomous genotype and menopausal status to the model with terms for the main effects only.
the CYP1B1 Val allele (31). Our results may differ from this report because of ethnic differences in genotype distribution, sample size and availability of information on potential confounders.
Our finding that the CYP1B1 Ser allele was associated with a decreased endometrial cancer risk may be due to alterations in the production of reactive catechol estrogens. Functional studies have concluded that the polymorphisms in exon 3 have significant effects on the catalytic function of CYP1B1 and demonstrate stronger carcinogenic hydroxylation activities compared with the wildtype (6, 8) . However variable K m values for estradiol metabolism catalyzed by different CYP1B1 variants have been observed, in part due to the use of different expression systems and analytical methodology (6EE8,13,32,33). Hanna et al. (8) and Shimada et al. (6, 34) observed that the ratio of product formation of 4-OH-E2 to 2-OH-E2 was higher for all variant forms of CYP1B1, potentially contributing to higher tissue levels of 4-OH-E2 (8) . In a previously conducted nested breast cancer casecontrol study, carriers of the CYP1B1 Leu allele and carriers of the CYP1B1 Ser allele had modestly higher estradiol levels but similar estrone and estrone sulfate levels (10) . The systematic evaluation of the functional significance and substrate specificity of all CYP1B1 variants and CYP1B1 haplotypes is essential to fully understand the contribution of CYP1B1 to estrogen-mediated carcinogenesis.
We did not observe a relationship between the COMT Val158Met genotype and endometrial cancer. Previous studies investigating the relationship of the COMT Val158Met genotype and breast cancer risk have had inconsistent results (35EE40). The COMT Met allele has also been studied in relation to ovarian cancer and endometriosis, and no overall risk has been observed (41, 42) . Recent evidence has suggested that the variation at Val158Met may not be sufficient to identify all genetic variation in COMT, and COMT haplotypes should be used in association studies to ascertain the contribution of COMT in disease etiology (43) .
The catechol estrogen, 2-OH-E2, inhibits COMT-catalyzed O-methylation of 4-OH-E2, significantly lowering the metabolic clearance rate of 4-OH-E2 compared with the rate for 2-OH-E2 (44, 45) . The CYP1B1 variant alleles have a higher catalytic efficiency for the 4-hydroxylation of estradiol, yielding more 4-OH-E2 (6, 8) . It is probable that 4-OH-E2 may accumulate in target tissues due to the inhibition of the O-methylation (44). Given the relationship of CYP1B1 and COMT and estrogen metabolism, we evaluated geneEEgene interactions. We did not observe any interaction between the polymorphisms; however, we had limited power to detect such an association.
There is also considerable interest in the interaction between polymorphic genetic variants and cancer risk by environmental risk factors. Since CYP1B1 and COMT are involved in estrogen metabolism, BMI and PMH use were chosen based on biological plausibility and their potential influence on estrogen levels. In postmenopausal women, BMI is a strong determinant of plasma estrogen levels (46) , and therefore obese women are at an increased risk of endometrial cancer (47), possibly in part Unconditional logistic regression adjusted for same variables as in e plus PMH use at diagnosis and age at menopause. g P-value for the nominal LRT comparing the nested model that included terms for all combinations of the dichotomous genotype and menopausal status to the model with terms for the main effects only.
CYP1B1 and COMT and endometrial cancer risk through the increased formation of reactive catechol estrogens by CYP1B1. Our results suggest that BMI does not modify the relationship between CYP1B1 or COMT genotypes and endometrial cancer. Similarly, we did not observe any geneEE environment interactions with PMH use. CYP1B1 is also involved in the activation of polycyclic aromatic hydrocarbons and heterocyclic aromatic amines to form mutagenic intermediates; therefore, CYP1B1 polymorphisms may dictate lifetime exposure levels to E2 metabolites and environmental carcinogens. We observed no effect modification by cigarette smoking status for the association between CYP1B1 genotypes and endometrial cancer risk.
Although the importance of estrogen and its metabolites in estrogen carcinogenesis is well established, the role of genetic susceptibility to endometrial cancer is not well understood. This study is the largest nested case-control study to address the relation of the CYP1B1 Leu432Val, CYP1B1 Asn453Ser and COMT Val158Met polymorphisms and endometrial cancer. Our data suggest an inverse association between the CYP1B1 Ser allele and risk of endometrial cancer risk. We observed no association of either the COMT Met or CYP1B1 Val alleles and endometrial cancer risk, although given our sample size, small to moderate effects could not be ruled out. The balance between phase I and phase II enzymatic reactions may influence the production of catechol estrogens; therefore, those individuals inheriting multiple variants within genes and across genes may be at an increased risk of disease. The identification of these person-to-person differences may help define subpopulations of women who have higher lifetime exposures to estrogen and its metabolites, and thus are more susceptible to oxidative damage and tumor initiation. The number of participants does not sum to total women because of missing data on genotype.`All cases and controls' include premenopausal and postmenopausal women and women with unknown menopausal status. b Conditional logistic regression model conditioned on the strata defined by the matching variables: age in 5-year intervals, menopausal status at blood collection, PMH use at blood draw, date of blood draw, time of blood draw and fasting status at blood draw.
c Conditional logistic regression conditioned on the strata defined by the matching variables, and adjusted for BMI at age 18, weight gain since age 18 until diagnosis, age at menarche, age at menopause, menopausal status at diagnosis, PMH use at diagnosis, first-degree family history of uterine cancer and colorectal cancer, parity, age at first birth and pack-years of smoking. d Unconditional logistic regression model regression adjusted for the matching variables: age in 5-year intervals, menopausal status at blood collection, PMH use at blood draw, date, time and fasting status at blood draw.
e Unconditional logistic regression adjusted for the matching variables: age in 5-year intervals, menopausal status at blood collection, PMH use at blood draw, date, time and fasting status at blood draw, BMI at age 18, weight gain since age 18 until diagnosis, age at menarche, first-degree family history of uterine cancer and colorectal cancer, parity, age at first birth and pack-years of smoking.
f Unconditional logistic regression adjusted for same variables as in e plus PMH use at diagnosis and age at menopause. g P-value for the nominal LRT comparing the nested model that included terms for all combinations of the dichotomous genotype and menopausal status to the model with terms for the main effects only.
